Artificial intelligence: opportunities and challenges in the clinical applications of triple-negative breast cancer - British Journal of Cancer
Source : https://www.nature.com/articles/s41416-023-02215-z
Triple-negative breast cancer (TNBC) accounts for 15-20% of all invasive breast cancer subtypes. Owing to its clinical characteristics, such as the lack of effective therapeutic targets, high invasiveness, and high...
Conclusions: In this review, we discussed the general principles of artificial intelligence, summarised its main applications in the diagnosis and treatment of TNBC, and provided new ideas and theoretical basis for the clinical diagnosis and treatment of TNBC.
Thymoquinone, piperine, and sorafenib combinations attenuate liver and breast cancers progression: epigenetic and molecular docking approaches - BMC Complementary Medicine and Therapies
Source : https://bmccomplementmedtherapies.biomedcentral.com/articles/10.1186/s12906-023-03872-6
Background Traditional herbal medicine has been used for centuries to cure many pathological disorders, including cancer. Thymoquinone (TQ) and piperine (PIP) are major bioactive constituents of the black seed (Nigella...
Conclusions: This study reported TQ and PIP as enhancers of the antiproliferative and cytotoxic effects of SOR and addressed the mechanisms, and identified molecular targets involved in their action.
Electrocardiographic and biochemical analysis of anthracycline induced cardiotoxicity in breast cancer patients from Southern Sri Lanka - BMC Cancer
Source : https://bmccancer.biomedcentral.com/articles/10.1186/s12885-023-10673-0
Background The clinical application of anthracycline chemotherapy is hindered due to the cumulative dose-dependent cardiotoxicity followed by the oxidative stress initiated during the mechanism of action of anthracyclines. Due to...
Conclusions: Since these results confirmed the unavoidable cardiotoxic changes following anthracycline chemotherapy, it is recommended to carry out long-term follow-ups in all patients who were treated with anthracycline therapy to increase their quality of life as cancer survivors.
Cost-effectiveness of abemaciclib | BCTT
Hormone receptor positive (HR+) breast cancer represents 70% of all primary breast cancers. Adjuvant endocrine therapy reduces the recurrence rate in these patients, however a significant proportion still experiences recurrence...
Conclusions: The addition of abemaciclib to adjuvant endocrine therapy in all high-risk ER , HER2- EBC patients is not cost-effective. However, using MRD detection to justify the addition of abemaciclib treatment dominates standard treatment in this cost-effectiveness analysis. Further evaluation of MRD detection in EBC by means of prospective...
Is another class of molecular targeted therapy an appropriate decision as the next treatment for progressive disease with initial molecular targeted therapy for luminal advanced/metastatic breast cancer? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36823129/
The sequential use of different classes of MTA did not affect the TTF of another MTA. Therefore, mTOR inhibitor + exemestane is a favorable treatment option administered after CDK4/6 inhibitor...
Conclusions: The sequential use of different classes of MTA did not affect the TTF of another MTA. Therefore, mTOR inhibitor exemestane is a favorable treatment option administered after CDK4/6 inhibitor hormone therapy. The CDK4/6 inhibitor hormone therapy is also suitable for patients previously treated with mTOR inhibitor exemestane....